Close Menu

asset acquisition

Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.

A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.

Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.

Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.

Population Genetics was formed to commercialize the IP portfolio of Sydney Brenner focused on high sensitivity and high specificity NGS detection.

The purchase provides Thermo Fisher with access to the $40 billion pharmaceutical contract development and manufacturing market.

Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.

The clinical genetics and genomics testing firm said the funding will help as it seeks to consolidate its presence in international markets.

The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.

CareDx's CareDx Pty subsidiary said it will pay up to $735,000 to Conexio as a percentage of revenues from products acquired in the deal. 

Pages

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.